麻豆视频

Global Pharmacovigilance Market Trends and Insights

Increasing Drug Consumption & Development Pipeline

The FDA cleared 50 new molecular entities in 2024, underscoring how breakthrough approvals widen post-marketing safety duties for every sponsor.^{[3]Food and Drug Administration, 鈥淒rug and Biologic Approvals,鈥� fda.gov} Gene therapies, CAR-T treatments and combination products pose unique risk profiles that require vigilant monitoring throughout the product life cycle. Conditional approvals further heighten real-world evidence (RWE) expectations, redirecting budgets toward continuous surveillance infrastructures. These dynamics lock pharmacovigilance teams into a long-term expansion cycle that sustains workload growth beyond clinical development.

Growing Incidence Of Adverse Drug Reactions (ADRs)

The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recently emphasized lifelong monitoring for CAR-T recipients after observing potential secondary malignancies.^{[4]European Medicines Agency, 鈥淧RAC Meeting Highlights,鈥� ema.europa.eu} Polypharmacy in elderly populations multiplies drug鈥揹rug interactions, pushing ADR case volumes higher. The pandemic-era vaccine rollout validated the importance of large-scale signal-detection networks capable of processing millions of safety reports within weeks.

Outsourcing Of PV Services To CRO/BPO Vendors

Sponsors are increasingly transferring full pharmacovigilance operations to CROs that maintain global compliance hubs and purpose-built AI engines. Such providers scale seamlessly across jurisdictions, enabling mid-sized biotechnology firms to meet complex rules without sustaining heavy fixed costs. Labor-arbitrage models in India and Eastern Europe also hold appeal, yet differentiation now rests on automated intake and predictive signal detection rather than pure cost savings.

AI-Enabled Signal Detection & Predictive Analytics

IQVIA targets a 50% reduction in routine case-processing spend by integrating large-language-model (LLM) copilots into daily workflows. Meanwhile, Oracle embedded advanced machine-learning features in its safety platform to triage literature alerts and automate narrative writing. Regulators have responded with draft guidance that sets validation expectations for AI use in safety management.

Cyber-Security & Data-Privacy Risks

Cloud deployment of sensitive patient data exposes safety systems to ransomware and nation-state intrusions. Recent healthcare breaches forced several sponsors to suspend EHR integrations while audits ensured no safety signal manipulation occurred. General Data Protection Regulation (GDPR) and similar laws mandate data-minimization and localization strategies that sometimes conflict with global analytics ambitions.

Shortage Of Specialised PV Talent & High Staff Turnover

Industry surveys project a 35% shortage of qualified pharmacovigilance professionals by 2030 as AI skills, regulatory knowledge and therapeutic specialization converge into a single profile. Organizations respond with apprenticeship programs and internal academies, yet ramp-up times can exceed two years, creating near-term bottlenecks.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Clinical Trial Phase: Post-Marketing Surveillance Drives Growth

Phase IV studies held 32.05% of pharmacovigilance market share in 2025, reflecting regulators鈥� demand for life-long monitoring of innovative therapies. The pharmacovigilance market size attached to pre-clinical safety assessments is projected to expand at a 12.88% CAGR thanks to risk-based early-phase analytics. Adaptive trial designs shorten Phases II and III, but heighten the importance of high-fidelity signal detection once products reach broad populations. Updated ICH E6(R3) guidelines compel sponsors to embed quality-by-design metrics across all phases, ensuring traceable safety data capture from first-in-human dosing. 

The pharmacovigilance market responds by integrating decentralized trials with direct-to-patient sampling and wearable sensors. AI models simulate off-target effects before first-patient dosing, giving companies a head start in risk-management planning. As conditional approvals rise, Post-Authorization Safety Studies (PASS) budgets eclipse traditional Phase III spends, locking Phase IV dominance into the long-term outlook.

By Service Provider: Outsourcing Accelerates Through Technology Integration

Contract outsourcing controlled 54.88% of overall revenue in 2025 and is forecast to grow at 13.48% through 2031, sustaining the largest slice of the pharmacovigilance market. In-house units retain critical decision-making but increasingly rely on hybrid models where CRO platforms process routine tasks. Strategic alliances such as Parexel鈥檚 multi-year AI pact with Palantir exemplify how tech-enhanced CROs cultivate competitive edge. 

The pharmacovigilance industry now values scalable data lakes, natural language processing (NLP) for scientific literature and robotic process automation in intake. As a result, even large pharmaceutical companies migrate workloads to external hubs in India, Ireland and Eastern Europe, consolidating fragmented vendor lists into master service agreements that guarantee AI investment roadmaps.

By Type of Reporting: EHR Mining Emerges as Technology Disruptor

Spontaneous reporting remained the backbone at 42.96% in 2025, yet the pharmacovigilance market size tied to EHR mining is expected to post the fastest 14.12% CAGR. Final FDA guidance on RWE opens the door for automated extraction of structured and unstructured clinical data to augment traditional case submissions. 

AI algorithms parse physician notes, lab results and imaging repositories to reveal hidden safety trends weeks earlier than spontaneous reports. Projects such as Sanofi鈥檚 ARTEMIS process more than 700,000 cases annually with NLP engines, freeing human experts for root-cause analysis. Standardization hurdles persist, particularly around data provenance, but the trajectory toward automated RWE ingestion is clear.

By End-User: Hospital Integration Transforms Safety Monitoring

Pharmaceutical companies held 58.91% of 2025 spending, yet hospital systems register the highest 14.18% CAGR as decentralized and pragmatic trials place safety responsibilities closer to the point of care. The pharmacovigilance market size associated with integrated delivery networks rises as hospitals deploy RWE platforms that feed near-real-time safety data to sponsors. 

BARDA鈥檚 five-year pact with Allucent illustrates how government funding accelerates hospital participation in countermeasure trials. Yet interoperability gaps and privacy regulations still slow cross-border data exchange, prolonging the transition period.

Geography Analysis

North America captured 43.62% of the pharmacovigilance market in 2025 due to high R&D intensity, advanced EHR penetration and clear regulatory expectations. AI pilots gain rapid acceptance as the FDA publishes step-wise validation frameworks, positioning the region as the global reference for digital pharmacovigilance. 

Europe follows with mature legislation underpinning the EudraVigilance network and new AI reflection papers that encourage innovation while demanding algorithm transparency. Focus on Advanced Therapy Medicinal Products brings specialized monitoring needs, sustaining investment through 2030. The pharmacovigilance market size for EU-based PASS grows alongside orphan-drug approvals. 

Asia-Pacific is projected to log a 13.12% CAGR, the fastest worldwide, as China鈥檚 regulatory reforms and India鈥檚 expanded clinical-trial landscape converge. ASEAN nations align labeling and electronic submission standards, simplifying multi-country safety campaigns. Investments in domestic biotech manufacturing stimulate demand for localized case-processing hubs. Middle East & Africa and South America add incremental growth where pharmacovigilance infrastructure scales with pharmaceutical import volumes and emerging manufacturing clusters.

Regulatory Landscape

Pharmacovigilance requirements continue to tighten around structured post-approval safety data management, electronic reporting formats, and signal management governance across major agencies. In the United States, the FDA reinforced postmarketing safety-reporting expectations through 2026 actions, including an April 2026 Federal Register update that mandates electronic submissions of postmarketing individual case safety reports (ICSRs) using ICH E2B(R3) data standards from 1 October 2026. This change brings forward system validation, data mapping, and gateway readiness for sponsors and service providers.

Internationally, ICH guideline adoption is reshaping operating procedures for global case processing and signal detection. The ICH E2D(R1) guideline on post-approval safety data management entered into effect in the European Union on 18 March 2026, and EU pharmacovigilance practice continues to anchor to EMA Good Pharmacovigilance Practices (GVP) modules and EudraVigilance reporting. Commission Implementing Regulation (EU) 2025/1466 (effective from August 2025) shifted expectations for how marketing authorisation holders monitor EudraVigilance and manage signals, prompting updates to internal SOPs and governance as workflows move beyond prior pilot-era approaches.

Value Chain Analysis

The pharmacovigilance value chain begins with safety-data generation and capture across pre-clinical and clinical programs, post-marketing spontaneous reports, scientific literature surveillance, and expanding real-world data feeds such as EHR mining. Data is then standardized and validated through intake, case triage, medical review, coding, narrative authoring, and signal detection workflows, before being packaged into regulatory outputs (ICSRs, periodic reports, and risk-management deliverables) for submission to authorities such as the FDA and EMA, as well as for internal benefit-risk decisioning.

Execution runs through sponsors (pharmaceutical and biotech companies), hospitals and trial sites, and specialized CRO/BPO and technology-enabled service providers such as IQVIA, ICON, Parexel, Cognizant, Accenture, Capgemini, and Wipro. A recurring bottleneck is interoperability and compliance change management as rules evolve, including the EU shift under Implementing Regulation (EU) 2025/1466 and the US movement toward ICH E2B(R3) for postmarketing ICSR submissions. Differentiation is concentrating in platform-based operations where automation and AI support higher-volume case processing and literature monitoring while keeping audit-ready traceability.

Market Opportunities and Future Outlook

Compliance-driven system upgrades and operating-model changes are creating near-term whitespace in safety operations modernization, particularly where organizations need to align internal processes to evolving standards such as ICH E2D(R1) (effective in the EU from March 2026) and build electronic postmarketing ICSR submission workflows for ICH E2B(R3) requirements in the United States from 1 October 2026. These changes favor vendors and service partners that can deliver validated data models, configurable workflows, and controlled automation across intake, processing, and reporting, without sacrificing inspection-ready traceability.

AI-native patient-safety delivery is moving beyond pilots into scaled deployments, expanding opportunity across both outsourcing and hybrid in-house models. In April 2026, Parexel acquired Vitrana to integrate an AI-enabled end-to-end pharmacovigilance platform into patient safety services. In June 2026, ArisGlobal announced two global pharmaceutical organizations selected NavaX AI to automate processing of structured and unstructured safety and clinical data, indicating continued procurement momentum for unified AI platforms. Newer distribution pathways also widen access for smaller sponsors and emerging-market operators, illustrated by June 2026 availability of Graph AI's Graph Safety Suite on Google Cloud Marketplace, which reduces friction for adopting PV tooling in cloud environments where data governance and validation requirements can be standardized.